跳至主要内容
临床试验/NCT01694342
NCT01694342Unknown不适用

Telomere Parameters Like Telomere Length, Telomerase Expression, Telomere Capture and Aneuploidy in Patients With Nonalcoholic Fatty Liver

Meir Medical Center1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2012年9月最近更新:
适应症

试验速览

阶段
不适用
入组人数
30
试验地点
1

研究概览

简要总结

Telomerase, through its regulatory function on telomere length may play an important role in immune function, cellular replicative life span, and carcinogenesis. Non-alcoholic fatty liver disease (NAFLD) is considered a benign condition, but in some cases, it may progress to cirrhosis and hepatocellular carcinoma. The risk factors for that evolution are not fully understood.

Our group showed in a previous study, that hTERT mRNA expression is lower in peripheral lymphocytes of patients with fatty liver, compared to healthy controls. This finding could explain the telomere shortening found previously in these patients by our group [20] and others [21]. Furthermore, we found higher rates of TC in these patients, probably due to an attempt to counteract the shortening of the telomeres and to stabilize them. This is through a different mechanism that is not telomerase-mediated.

Telomere capture is considered an alternative way to maintain telomere length and chromosomal stability [3]. It is a more common mechanism for chromosome stabilization and repair, in contrast to the telomerase-mediated process of chromosome healing and elongation This study aimed to evaluate mechanisms of telomere homeostasis like telomere shortening, telomerase activity, telomere capture and aneuploidy in patients with NAFLD in order to explain previous findings of telomere shortening in these patients.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • age over 18
  • diagnosis of fatty liver

排除标准

  • no malignancy
  • no eligible to sign the consent paper

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Telomere Parameters in Patients With Nonalcoholic... | 临床试验